Jubilant Biosys and Endo Pharmaceuticals have expanded their year-old oncology drug discovery alliance. The decision follows Jubilant’s achievement of an early-stage milestone.
The collaboration involves joint target discovery and Jubilant generating and delivering preclinical anticancer candidates to Endo. Jubilant Biosys is a subsidiary of India-based custom research and manufacturing services company Jubilant Organosys. The firm provides drug discovery and development services to the pharma industry worldwide.
“This collaboration further reinforces the concept of globally leveraged R&D,” comments Jubilant’s Sri Msur, CEO and president of global drug discovery and development. “This expansion is testimony to Jubilant’s focus on building worldclass oncology capabilities, among other therapeutic areas.”